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Abstract: Recent data from a national survey highlighted a significant difference in obesity rates in young fragile X males 
(31%) compared to age matched controls (18%). Fragile X syndrome (FXS) is the most common cause of intellectual 
disability in males and the most common single gene cause of autism. This X-linked disorder is caused by an expansion of 
a trinucleotide CGG repeat (>200) on the promotor region of the fragile X mental retardation 1 gene (FMR1). As a result, 
the promotor region often becomes methylated which leads to a deficiency or absence of the FMR1 protein (FMRP). 
Common characteristics of FXS include mild to severe cognitive impairments in males but less severe cognitive 
impairment in females. Physical features of FXS include an elongated face, prominent ears, and post-pubertal 
macroorchidism. Severe obesity in full mutation males is often associated with the Prader-Willi phenotype (PWP) which 
includes hyperphagia, lack of satiation after meals, and hypogonadism or delayed puberty; however, there is no deletion at 
15q11-q13 nor uniparental maternal disomy. Herein, we discuss the molecular mechanisms leading to FXS and the 
Prader-Willi phenotype with an emphasis on mouse FMR1 knockout studies that have shown the reversal of weight 
increase through mGluR antagonists. Finally, we review the current medications used in treatment of FXS including the 
atypical antipsychotics that can lead to weight gain and the research regarding the use of targeted treatments in FXS that 
will hopefully have a significantly beneficial effect on cognition and behavior without weight gain. 
Received on: March 15, 2011 - Revised on: March 30, 2011 - Accepted on: March 31, 2011 
Keywords: Fragile X, trinucleotide repeat, Prader-Willi phenotype, obesity, mGluR antagonists. 
INTRODUCTION 
  Obesity is a common problem in the fragile X syndrome 
(FXS) and we can learn from the molecular overlap between 
FXS and other obesity syndromes, particularly Prader-Willi 
syndrome (PWS). A recent national survey from 885 
families found similar obesity rates between FXS adults in 
comparison to typically developing adults [1]. However, 
body mass index (BMI) data collected from 718 children, 
with an age <20 years, found male children with FXS had a 
higher prevalence rate of obesity (31%) when compared to 
age matched control children (18%) [1]. FXS is the most 
common cause of inherited intellectual disability (ID) and 
the most common known single gene cause of autism [2, 3]. 
It is caused by a CGG expansion greater than 200 repeats in 
the 5’ untranslated region in the fragile X mental retardation 
1 (FMR1) gene. The expanded number of repeats can result 
in either a premutation (55 to 200 repeats) or a full mutation 
(>200 CGG repeats) status [4, 5]. The full mutation usually 
leads to methylation of the promoter region so that little or 
no FMR1 mRNA is produced with lack of the FMR1 protein 
(FMRP) [6-8]. In those with FXS the level of cognitive 
ability and the severity of the physical phenotype correlates  
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with the level of FMRP [9]. The lack of FMRP can lead to 
accelerated preadolescent growth in FXS but a diminution of 
the normal pubertal growth spurt [10]. The knockout mouse 
model of FXS has enhanced growth and obesity that can be 
reversed by the use of targeted treatments specifically 
mGluR5 antagonists [11].  
  Finally, in less than 10% of individuals with FXS there is 
an unusual phenotype associated with severe obesity, 
hyperphagia, hypogonadism or delayed puberty and termed 
the Prader-Willi phenotype (PWP), although it is not 
associated with a deletion of 15q11-q13 nor due to 
uniparental maternal disomy 15. Instead a lower expression 
of the CYFIP1 gene, located in the 15q11-q13 region, 
encodes for the cytoplasmic FMR1– interacting protein 1 
(CYFIP1), a protein that works in concert with FMRP, is 
associated with the PWP [12]. In addition, those individuals 
with the PWP and FXS have an autism spectrum disorder 
(ASD) at a higher frequency than those with FXS alone, 
without the PWP. 
  To better understand the association between obesity and 
FXS in addition to the molecular overlap with other 
disorders, we will review the function of FMRP in addition 
to the phenotypic features of FXS and fragile X- associated 
disorders. Treatment endeavors, particularly those that utilize 
atypical antipsychotics, can exacerbate the weight gain of 
individuals with FXS making obesity a significant problem. Fragile X Syndrome  Current Genomics, 2011, Vol. 12, No. 3    217 
Therefore, the use of new-targeted treatments in FXS has the 
potential to reverse or alleviate the obesity in affected 
individuals as it does in the FMR1 knockout (KO) mouse. 
MOLECULAR BASIS OF FXS: FMRP DEFICIENCY 
  FMRP is expressed in many tissues but is mainly 
concentrated in the neuronal cells in the brain and testes [13, 
14]. FMRP is an RNA-binding protein that selectively binds 
to as much as 4% of all mRNA in mammalian brains [15]. 
While FMRP deficiency is the cause of FXS, one 
preliminary report shows a deficiency of FMRP in the brains 
of individuals with neuropsychiatric disorders that do not 
have an FMR1 mutation [19]. Post-mortem brain tissue from 
the lateral cerebella of controls compared to subjects with 
psychiatric disorders revealed FMRP was reduced by 78% in 
the brains of those with schizophrenia, 68% in major 
depression, and 60% in brains of those with bipolar disorder 
as compared to control brains [19]. 
  FMRP is involved in multiple roles including the 
transport of mRNAs to the synapses [16, 17] and repression 
of mRNA translation (perhaps for both initiation and 
elongation phases) [3, 4]. Napoli and colleagues [18] 
demonstrated that FMRP binds to CYFIP1 (Cytoplasmic 
FMRP Interacting Protein 1) and this complex binds to 
eIF4E, a translation initiation factor involved in the directing 
of ribosomes to the cap structure of mRNAs. The resulting 
eIF4E-CYFIP1-FMRP complex is present at synapses. 
Synaptic stimulation leads to the release of CYFIP1 from 
eIF4E, allowing translation to occur [18].  
 The  FMR1 gene is located on chromosome Xq27.3 with 
the mature mRNA composed of 17 coding exons spanning 
38kb. Several highly conserved regions including the NLS 
domain (exons 5-6), NES domain (exon 14), the first KH1 
domain (exons 7-9), the second KH2 domain (exons 9-11), 
and the RGG (exon 15) are found [15]. Amino acid 
sequences encoding for the nuclear export signal (NES) and 
nuclear localization signal (NLS) demonstrate that FMRP 
travels back and forth between the nucleus and cytoplasm. 
However, the roles of FMRP within the nucleocytoplasmic 
space are not fully understood, although it is known that 
FMRP binds and transports mRNAs to the synapse. FMRP 
can also stabilize the mRNAs (PSD-95 mRNA) or enhance 
the degradation of mRNAs (Nfxf1 mRNA) [20] and appears 
to shape the pattern of mRNA regulation throughout 
development [20]. 
  Most of the information known about FMRP involves the 
interactions between the local dendritic mRNA bindings 
through attachments identified by the K homology (KH) 
domains and a RGG box, composed of arginine and glycine 
residues. Proteins with these types of motifs have been 
shown to be RNA-binding proteins. The significance of 
these attachments between polyribosomes and FMRP was 
confirmed in a case study where molecular analysis revealed 
normal levels of FMRP in an individual with a point 
mutation in 1 of the 2 KH domains, preventing proper 
bindings and thus the assemble of RNP complexes [21, 22]. 
  Complementary DNA (cDNA) of most of the associated 
mRNAs was found using protein complex 
immunoprecipitation (Co-IP) techniques on FMRP and then 
identified through microarrays [23]. Many FMRP interacting 
mRNAs have yet to be discovered but those that have been 
identified as targets of FMRP include Arc (activity-regulated 
cytoskeleton-associated protein), CamKII alpha (calcium/ 
calmodulin-dependent protein kinase), eEF1A (elongation 
factor 1a), GluR1/2, Sapap3/4 (postsynaptic scaffolding 
proteins; bind to PSD-95), RGS5 (regulator of G-protein 
signaling 5), and GABAA [23]. Additional research 
involving Co-IP or in-vitro methods found APP (amyloid 
beta (A4) precursor protein), FMR1, MAP1B (microtubule-
associated protein 1B), PSD-95, and Sema3F (semaphorin 
3F) binding to FMRP through a G-quartet-like structure that 
has been shown to interact with the RGG box in vitro [15]. 
Results from several studies show that most of the mRNA 
targets are found to be mGluR stimulated (with the exception 
of Sema3F) and localized within the dendrites (with the 
exception of APP) [15]. Together with FMRP, microRNAs, 
ribosomes, and proteins form mRNP (messenger 
riboucleoprotein) complexes that are transported down to the 
dendritic spines in anticipation of an action potential to 
signal the start of protein synthesis [24]. These mRNP 
complexes are vital in post-transcriptional processes because 
of their specificity for binding and interacting with 
recognizable transcripts only, which suggest the flow of 
transcripts is not as generic as previously thought, but rather 
a highly precise mechanism performed through central gene 
expression [25]. 
  The necessity for local translation to take place in the 
dendritic spines through the binding of these mRNA targets 
is vital for synaptic plasticity. This ability to respond quickly 
to stimuli by adapting in synaptic strength is crucial for 
evolutionary conserved processes such learning and memory 
[11]. This mechanism requires the presence of protein 
machinery proximal to the distal synaptic connections, as 
opposed to the perinucleur regions of the cytoplasm, to 
quickly and efficiently respond to incoming signals and 
remodel accordingly. Visualizations from FMR1 KO mice 
and FXS human tissues reveal an increased density of 
immature elongated spines located on the dendrite [26]. 
Dendritic spines are used to increase the area of contact 
between other neurons and support the electrical signals 
from action potentials. Healthy spines in WT mice reveal 
bulbous heads at the end of necks that appear plump with 
full knobs enriched with AMPA (alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid) receptors, GluR 
(glutamate receptors), and NMDA (N-methyl-D-aspartate) 
receptors. The dendrites of FXS look immature due to the 
loss of these AMPA and NMDA receptors. Furthermore 
these immature spines show a reduction in synaptic vesicles 
docking at the presynaptic active zone and a smaller 
postsynaptic density [27]. FMR1 KO mice show the same 
immature spine profiles and have learning and memory 
problems due to a decrease in synaptic plasticity [28].  
  FMRP is believed to affect several pathways including 
the mGluR signaling pathway. Glutamate is the principal 
excitatory neurotransmitter and the dynamics of fluctuations 
can result in two key mechanisms for learning: Long Term 
Depression (LTD) and Long Term Potentiation (LTP). LTD 
is a form of synaptic plasticity that is regulated by activation 
of mGluRs that leads to an internalization of AMPA 
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[29], suggests that the disruption of the role of FMRP as 
suppressor of regulation on the mGluRs leads to the over 
internalization of AMPA receptors. FMR1 KO studies 
demonstrated activation of mGluR in the hippocampal field 
CA1 and in cultured hippocampal neurons leading to 
exaggerated LTD when compared to WT mice [30, 31]. The 
mGluR hypothesis is also supported by the rescue of 
audiogenic and limbic seizures, characteristic of FXS [32] in 
FMR1 KO mice treated with MPEP, a selective 
noncompetitive antagonist of mGluR. Interestingly, the 
enhanced weight gain in FMR1 KO mouse which is 30% 
increased compared to wild type [33] is rescued when the 
FMR1 KO mice are crossed with an mGluR5 deficient 
mouse [33]. 
  A recent double KO study brought attention to cell 
signaling through additional G protein coupled receptors 
known as regulator of G-protein signaling (RGS) proteins. 
The double knockout (FMR1 / RGS4) mice were able to 
rescue a subset of molecular abnormalities seen in FXS, 
including the restoration of GABA expression and the 
normalization of PSD-95 mRNA levels [34]. In addition, 
these double knockout mice had normal weight gain and 
positive social outcomes, displayed from two independent 
socialization tests with no statistical significance when 
compared to WT mice. In comparison, the FMR1 KO had a 
13-17% increase of weight when compared to the other 
groups and social avoidance behavior [34]. However, 
macroorchidism and hyperactivity were not affected by the 
elimination of the RGS4 protein and the reduction of mGluR 
signaling. Previous studies of mGluR5 antagonists showed 
no rescue of macroorchidism in the KO mouse [11].  
  Ampakines, positive AMPA receptor modulators, are 
another form of treatment that can be given to individuals 
with FXS but no significant effect was seen in a controlled 
trial [35]. Ampakines are thought to enhance memory 
because of interactions with BDNF (Brain Derived 
Neurotrophic Factor) [35], which has been shown to correct 
hippocampal LTP in some disorders impacted by memory 
impairment. BDNF levels are not reduced in FMR1 KO 
mice; however, it is thought to be mis-localized in 
hippocampal and neocortical neurons [36]. Besides the 
glutamargeic system, AMPA receptors are impacted from 
the dopamergic system as well. Hyperactivity, impulse 
control, and attention deficits are characteristic of children 
with FXS and are thought to arise from dysfunction in 
frontal-subcortical circuits due to a reduced dopaminergic 
drive [37]. In one national survey that involved data 
collected from 976 full mutation males and 259 full mutation 
females; 80% of parents indicated their child had been co-
diagnosed or treated for attention problems [38].  
  Another neurotransmitter impacted in FXS is GABA, the 
inhibitory neurotransmitter of the central nervous system, 
which, in conjunction with glutamate, helps weaken 
selective synaptic strength [39]. The GABA hypothesis of 
FXS hypothesizes an altered gamma-aminobutyric (GABA) 
receptor signal [11] that affects neuronal synaptic plasticity 
and leads to developmental difficulties. The mRNA coding 
for GABA receptor subunits are targeted by FMRP in the 
cytoplasm [11] and found, in addition to other elements in 
the GABA signaling pathway, to be down regulated in 
individuals with FXS [40]. The GABAA receptor proteins 
appear to be down regulated in the absence of FMRP in the 
fragile X knockout mice [40, 41]. Recently, the testing of 
targeted treatments of the GABA pathway has begun in an 
effort to up-regulate the pathway to near normal levels. 
These include drugs such as Arbaclofen, a GABAB agonist, 
and Ganaxolone, a GABAA agonist [11, 42]. Trials of these 
drugs in animals and humans with FXS are ongoing. 
  Since FMRP is thought to function as a suppressor of 
translation, the absence of FMRP manifests as an up-
regulation of several proteins since there is a lack of 
suppression in FXS [43]. This absence of inhibition from 
FMRP translates into dysfunction of synaptic plasticity and 
results in several cognitive impairments and behavioral 
problems in FXS.  
  Thus, FMRP regulates local dendritic mRNA translation 
through binding interactions between various mRNP 
complexes that suppresses protein synthesis and also mGluR 
pathways. This results in an over internalization of AMPA 
receptors which leads to a magnification of LTD: one of the 
two key processes that facilitates synaptic plasticity to 
augment learning and memory mechanisms. In addition, 
interactions between FMRP and neurotransmitter systems 
have revealed the reversal of increased weight phenotypes 
through mGluR antagonists. 
THE PHENOTYPE OF FXS AND THE PRADER-
WILLI PHENOTYPE 
  Classic physical features often seen in adults with FXS 
include an elongated face with a prominent forehead and 
macroorchidism, 2 or 3 times the normal size by mid-
adolescence. In addition, changes in elastin fibers in 
connective tissue relate to abnormalities, such as prominent 
ears, soft skin, flat feet, and hyperextensible finger joints. 
Medical problems often seen in males with FXS include 
strabismus (8 to 36%), seizures (20%), and otitis media 
(85%) [44].  
  The behavioral phenotype of FXS includes significant 
anxiety, attention deficit hyperactivity disorder (ADHD), and 
hyperarousal to sensory stimuli [45-47]. Surveys of 
individuals with FXS show there is enhanced food selectivity 
in the population as well, with the most common type of 
food sensitivity due to texture (as compared to generalized 
food refusal or food selectivity due to type of food) [1]. In 
addition, these patients tend to perseverate on topics 
sometimes meeting criteria for obsessive-compulsive 
disorder (OCD) [45]. When their obsessions are focused on 
food then overeating is a problem and this is commonly seen 
in the PWP. Although cases involving the removal of food 
items from the garbage, hoarding or raiding the refrigerator 
at night are less common in FXS as compared to PWS. 
However, night eating is often seen in PWP because sleep 
disturbances are common in FXS and they often are up at 
night and wander in the house [48]. 
  Ten percent of individuals with FXS may have PWP with 
severe obesity. The PWP of FXS was first recognized in 
cases characterized physically by their short stature and 
enhanced weight [49]. Their distinctive physical phenotype 
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disorder cause by a paternally derived deletion in the 15q11-
q13 region or uniparental maternal disomy, but further DNA 
analysis confirms no abnormalities for both copies of the 15q 
chromosomes in PWP individuals [12]. 
  Several separate studies reported within the last two 
decades describe the unusual obesity trend noted in the PWP 
[50, 51]. These PWP individuals were described as having a 
lack of satiation and hyperphagia with onset in the first 
decade of life leading to truncal obesity with fat deposits 
settling primarily around the torso and abdomen. Among the 
individuals first described with PWP [50], 2 were first 
classified as having PWS before cytogenetic testing was 
available and later nullified and confirmed to have FXS 
instead. This sub-phenotype of FXS was further 
distinguished by a deviation away from the traditional 
Martin-Bell phenotypic features. Most of these individuals 
with the PWP were described as having a full round face, 
areas of hypopigmentation, and microorchidism instead of 
the typical long face, prominent ears and macroorchidism 
associated with conventional FXS. In addition, they 
displayed traits that resembled PWS such as severe obesity 
(>2SD) and short hands/ feet (Fig. 1). However, none of the 
individuals with PWP reported having severe hypotonia 
problems leading to failure to thrive during infancy, which is 
commonly noted in PWS [12, 49, 50]. Another 13 cases with 
the PWP and confirmed FXS were reported in 2007 [12]. All 
13 had hyperphagia with an average onset at 4.7 years. 
Consistent with the previous reports of PWP, the actual onset 
of hyperphagia presents later in childhood in comparison to 
children with PWS. Another distinction was found in eating 
habits with PWP regarding binge eating to the point of 
vomiting, whereas those with PWS have decreased emesis 
[12]. Precautions such as locking up refrigerators were 
undertaken in occasional cases when individuals would 
devour anything available including raw meat and whole 
sticks of butter due to their lack of satiation while eating 
(Table 1).  
  Hypogenitalism and hypogonadism was noted in 6 out of 
the 13 cases with PWP reported by Nowicki et al. [12]. 
Those with hypogonadism in the PWP of FXS eventually 
developed large testes during puberty consistent with FXS in 
our experience. None of the 13 cases seen by Nowicki et al. 
[12] reported a short stature with average height at the 73rd 
percentile. Of the 13 PWP individuals identified by Nowicki 
et al. [12], 8 had IQ data available and FSIQ ranged between 
36 and 49 with one exception of a mosaic male who had a 
FSIQ of 75. These data are consistent with previous reports 
of cognitive abilities in those with FXS [52]. Interestingly, a 
higher frequency of autism spectrum disorders was reported 
in those with the PWP compared to those with FXS without 
the PWP [12]. 
  Earlier case reports of PWP in FXS hypothesized that 
features such as the short stature and obesity was a result of 
hypothalamic dysfunction [49]. Further endocrine studies in 
FXS have demonstrated hypothalamic-pituitary-adrenal axis 
dysfunction. In the KO mouse model, there is an elevated 
level of corticosterone as well as other stress hormones [53]. 
Cortisol elevations have also been seen in those with FXS 
particularly at bedtime compared to controls [54]. 
OXIDATIVE STRESS IN FXS 
  Individuals with FXS have a higher level of 
mitochondrial oxidative stress due to the absence of FMRP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     A      B       C  
Fig. (1). A, B, & C Prader-Willi Phenotype. 
A 9 year, 8-month-old full mutation fragile X boy with the Prader-Willi phenotype. He was referred to the Medical Genetics Clinic where 
Prader-Willi syndrome was ruled out through methylation testing. A karyotype showed a normal male, 46, XY. Fragile X testing was done 
and came back abnormal with mosaicism for a full mutation and a low level 105 repeat premutation. Notice the round face and prominent 
ears (Fig. 1A), short fingers (Fig. 1B), and truncal obesity (Fig. 1C). 220    Current Genomics, 2011, Vol. 12, No. 3  McLennan et al. 
[55]. There is an increase in the production of reactive 
oxygen species [55] as a byproduct of normal cellular 
function. These reactive oxygen species may affect neural 
plasticity in the brain as in other syndromes including autism 
[56, 57]. One of the many enzymes responsible for reducing 
the negative effects of reactive oxygen species is NADH-
oxidase. In the central nervous system, normal functions of 
NADH-oxidase may play a vital role in neuronal signaling 
and memory, while the overproduction of reactive oxygen 
species can lead to neurotoxicity and neurodegeneration 
[58]. In FXS there is also a deficit in the antioxidant system 
to control reactive oxygen species and this appears to be 
related to an alteration in the glutathione system [55]. 
  The over-production and lack of control of reactive 
oxygen species have lead to research to treat FXS 
individuals with anti-oxidants. High doses of lipid-soluble 
antioxidants, especially alpha-tocopherol, have been 
experimentally shown to reverse hyperactivity, anxiety, and 
corticosterone elevation in the KO mice [59]. Melatonin, 
which is an antioxidant in addition to a sleep hormone, has 
been found to have effects similar to alpha-tocopherol in the 
KO mice with improvement in synaptic connections and 
behavioral measures [60]. Recently mitochondrial problems 
have also been documented in those with the premutation 
with or without the fragile X-associated tremor ataxia 
syndrome (FXTAS) [61]. Such studies suggest the need to 
further study the benefit of antioxidants in those with the 
premutation and the full mutation. 
  Obesity and hyperphagia features in PWS have been 
linked with a 187kb microdeletion on chromosome 15q11-
q13 for a non-coding region associated with small nucleolar 
RNA (snoRNA), including snoRNA HBII-85, that modify 
other small nuclear RNAs (snRNA) by directing site-specific 
2'-O- methylation of substrate RNAs [62]. While there is 
some early evidence of alternative splicing and variations of 
FMRP isoforms affecting synaptic plasticity [63], studies 
have yet to determine if these isoforms also play a role in 
other phenotypic domains such as the characteristics seen in 
the PWP [12]. 
AUTISM  
  Autism is a common problem in those with FXS and 
occurs in approximately 30% of males with FXS. An 
additional 30% of males who did not meet criteria for autism 
are diagnosed with ASD [64, 65]. In those individuals with 
the PWP the rate of autism was 54% which was higher than 
those without the PWP [12]. Screening for the FMR1 
mutation in those affected by autism or ASD is medically 
indicated and the rates can be as high as 6% positive for FXS 
[3]. In a recent study of those with FXS and autism and in 
those with autism secondary of a 15q duplication, there was 
abnormal expression of GPR155 (G protein coupled receptor 
155) in both groups which is a gene regulated by CYFIP1 
[66]. This may be part of the link between the PWP and 
autism.  
  It has been shown that those individuals diagnosed with 
PWS are also at increased risk for autism [67]. Individuals 
with both diagnoses show a high level of similarity with 
regard to overall repetitive and ritualistic behavior [68]. 
Studies are now showing that behaviors are similar enough 
to be predictive of the family of disorders at 15q11-q13 with 
high accuracy [69]. In PWS, the first microdeletion between 
Table 1.  Differences and Similarities between Prader-Willi Phenotype, Prader-Willi Syndrome, and Fragile X Syndrome 
  Facial Features  Physical Features  Behavioral Features  Macroorchidism  Other 
Prader-Willi 
Phenotype 
[12] 
Round shaped face; almond 
shaped eyes; ears may or may 
not be prominent 
Obesity; delayed 
puberty; small penis; 
hypotonia 
Developmental delay; 
food related behavior 
problems; hyperphagia; 
transitions difficult; 
emesis is common; 
perseverative speech; 
behavior problems; hand 
flapping; poor eye contact; 
autism or ASD; OCD 
Yes, with puberty   
Prader-Willi 
Syndrome 
[83] 
Almond shaped eyes; 
strabismus; thin upper lip; 
downturned corners of mouth; 
viscous saliva; enamel 
hypoplasia 
Short stature; obesity; 
osteoporosis; small 
hands/feet; 
hypopigmented hair, 
nails, and skin; frontal 
hair upsweep 
Learning disabilities; 
hyperphagia; skin/anal 
picking; food related 
behavior problems; 
transitions difficult; 
stubbornness; 
perseverative speech; 
OCD 
No  Unusual jigsaw 
puzzle skill; high 
pain tolerance 
Fragile X 
Syndrome 
[84] 
Large, prominent ears; long, 
narrow face; puffiness around 
eyes; narrow palpebral fissures; 
large head relative to body; 
epicanthal folds; strabismus; 
hypotonia; long and narrow eye 
openings; prominent jaw; high 
arched palate 
Flat feet; hand calluses; 
single palmar crease; 
double jointed thumbs; 
hypotonia 
Tantrums; hyperactivity; 
anxiety; irritability; autism 
or ASD; hand flapping and 
poor eye contact; 
hyperarousal 
Yes with puberty; 
average range: 40-60 
ml 
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BP1 to BP3, known as the type 1 deletion, includes NIPA1, 
NIPA2, and CYFIP1 and these genes are suspected to have 
the greatest impact in cognitive and behavioral 
manifestations in PWS [70, 71]. Individuals with Prader-
Willi type 1 deletions have more severe cognitive deficits 
and were more prone to obsessive compulsive disorders and 
poor adaptive behavior scores than those who had type 2 
deletions or uniparental maternal disomy. Furthermore, they 
showed greater self-injurious behavior and deficits in 
adaptive behavior [70]. This is reminiscent of the more 
severe behavioral problems seen in those with the PWP of 
FXS who have lowered CYFIP1 compared to those with 
FXS without the PWP [12].  
  While autism is a heterogeneous disorder with multiple 
genetic and perhaps environmental factors contributing to 
the etiology; the CYFIP1 gene continues to show a 
molecular link between PWS, PWP in FXS, and autism. 
Evidence shows that CYFIP1 dysregulation occurs in almost 
all individuals with FXS but is down-regulated in the PWP 
subpopulation. The dysregulation of CYFIP1 was further 
confirmed in another in vivo study through the dysregulation 
in ASD of two other genes, JAKMIP1 and GPR155, 
downstream of CYFIP1 [66]. Nowicki et al. [12] reported 
that the mRNA levels for CYFIP1 in the PWP were 
significantly reduced compared to those with FXS and to 
controls. The reduced expression of CYFIP1 mRNA may 
provide an obstacle in the neuronal plasticity of the brain 
resulting in the manifestation of higher rates of autism due to 
the dysregulation of neuronal connections. Model studies of 
CYFIP1 mutants implicate that CYFIP1 is involved in 
several processes such as in axonal path finding and growth 
and synaptic morphology at the neuromuscular junction [72]. 
In addition to the local translation of protein, which is 
regulated by FMRP, the physical remodeling of the 
cytoskeleton must be able to adapt in response to 
extracellular signals as well for normal neuronal 
morphogenesis and connectivity to occur [72]. The 
RhoGTPase pathway has been shown to control the actin 
reorganization in the cytoskeleton [73]. CYFIP1 has been 
shown to interact with the RhoGTPase systems and FMRP 
through Rac1, a RhoGTPase family member, in Drosophila 
[72]. The loss of FMRP in vitro and in vivo causes synaptic 
aberrations that are remarkably similar to those observed in 
mutants affecting the Rac1 signaling pathways [28, 74]. In 
Drosophila, CYFIP1 was found to be a crucial effector of 
dRac1 and provided a link between FMRP translation and 
the RhoGTPase actin reorganization processes in a unique 
pathway to modulate neuronal morphogenesis.  
TREATMENT OF FXS 
  Current treatments of FXS include the use of stimulants, 
selective serotonin reuptake inhibitors (SSRIs), atypical 
antipsychotics and alpha agonists [75]. ADHD symptoms are 
seen in the majority of boys and about 30% of girls with 
FXS [75]. Although stimulants usually decrease the appetite, 
the atypical antipsychotics usually increase the appetite and 
these medications are commonly used in FXS to stabilize 
mood and decrease aggression. In a clinical survey of a large 
population of children and adults with FXS, 80% responded 
to > 1 ayptical antipsychotic [76]. Risperidone and 
aripiprazole are most commonly used with advertising 
suggesting that aripiprazole has less weight gain associated 
with use. However, even though low doses of aripiprazole 
are typically used in FXS because higher doses can be 
associated with significant agitation, weight gain is still 
commonly seen. Perhaps the genetic predisposition to 
obesity in FXS will lead to more frequent weight gain with 
the use of these medications compared to other individuals 
without the absence or deficiency of FMRP. 
  The new targeted treatments for FXS that are focused on 
reversing the neurobiological problems associated with a 
lack of FMRP have not caused obesity. In fact, in the mouse 
model, treatment can rescue the excessive weight gain [11, 
33]. These targeted treatments include mGluR5 antagonists 
that can rescue the dendritic spine deficits, seizures, weight 
gain, cognitive deficits and behavioral problems in the KO 
mouse [11, 33]. Human studies have been initiated with 
benefits seen behaviorally and in prepulse inhibition (PPI) in 
adult subjects with FXS after the use of one dose of 
fenobam, an mGluR5 antagonist [77]. Recently, the 
European trial has published data regarding the use of 
AFQ056, another mGluR5 antagonist, in adults with FXS 
which demonstrated efficacy in behavioral measures for 
those with a full mutation only, but not in those who were 
mosaic [78]. The preliminary data on the use of Arbaclofen, 
a GABAB agonist that lowers glutamate at the synapse, 
demonstrate efficacy in children and adults with FXS and 
autism or FXS and social deficits rated by the Aberrant 
Behavioral Checklist [79]. This targeted treatment is also 
currently being studied in children and adults with idiopathic 
autism without FXS although the results regarding weight 
changes are not yet available.  
  A new targeted treatment found to be effective in 
rescuing the dendritic abnormalities in the KO mouse when 
given after birth is minocycline. This medication can lower 
the matrix metalloproteinase 9 (MMP9) levels, which are 
elevated in the KO mouse and strengthen and mature 
synaptic connections [80]. Since this medication is used 
clinically to treat acne and readily available by prescription, 
it has been used by many families and a survey of benefits 
and side effects have demonstrated that approximately 70% 
of families observed benefits [81]. The side effects were 
mainly gastrointestinal including loss of appetite, loose 
stools or GI intolerance of the medication. An open trial by 
minocycline in adolescent and young adults with FXS also 
demonstrated efficacy [82] and currently a controlled trial in 
children and adolescents with FXS is taking place. We do 
not yet know whether minocycline will lead to weight loss 
and whether the appetite suppressing effects are related to 
the direct effect on the stomach by minocycline or to a 
neurochemical change. Clinically, the use of a probiotic has 
helped to decrease the frequency of loose stools because it 
replaces the GI bacteria with Lactobacillus species to 
overcome the negative effects of minocycline’s influence on 
reducing GI flora [81]. 
CONCLUSIONS 
  The field of FXS is exciting because of expanding 
knowledge in molecular biology and the advances in the use 
of targeted treatments to reverse the neurobiological 
abnormalities in affected individuals. Further research will 222    Current Genomics, 2011, Vol. 12, No. 3  McLennan et al. 
clarify why there is enhanced weight gain in both the animal 
models and in those affected with FXS. The PWP is an 
interesting bridge between PWS and FXS and further 
elucidation of the hormonal and molecular dysfunction in 
PWP will lead to new treatments that may be of benefit to 
both FXS and PWS. 
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